Lysosome‑associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer

Huang,Yue‑Nan; Guo,Xin; You,Liu‑Ping; Wang,Chun‑Jing; Liu,Jia‑Qi; Li,Yun‑Long

doi:10.3892/ol.2017.6899

Lysosome‑associated protein transmembrane4β is involved in multidrug resistance processes of colorectal cancer

Authors:
- Yue‑Nan Huang
- Xin Guo
- Liu‑Ping You
- Chun‑Jing Wang
- Jia‑Qi Liu
- Yun‑Long Li
View Affiliations

Affiliations: Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Intensive Care Unit, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
Published online on: September 6, 2017 https://doi.org/10.3892/ol.2017.6899
Pages: 5229-5234
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of the most common reasons for cancer‑associated mortality worldwide. The present study aimed to investigate the drug resistance mechanism of the oxaliplatin (OXA)‑resistant HT‑29 cell line (HT‑29/L‑OHP) and examine the expression of lysosome‑associated protein transmembrane 4β (LAPTM4β), a drug resistance‑associated gene. In the present study, a drug concentration gradient method was used to establish the drug‑resistant HT‑29/L‑OHP cell line. Cell apoptosis was analyzed by flow cytometry. LAPTM4β mRNA expression was examined by reverse transcription‑quantitative polymerase chain reaction analysis and LAPTM4β‑35 expression was examined by western blot analysis. Cell morphology of the HT‑29/L‑OHP drug‑resistant cell line was examined. The results indicated that the intercellular space among HT‑29 cells was small, with aggregative growth while the intercellular space among HT‑29/L‑OHP cells was large, with scattered growth. The apoptotic rate in HT‑29/L‑OHP cells (11.7%) was significantly lower compared with that in HT‑29 cells (17.7%) (P<0.05). LAPTM4β mRNA expression in HT‑29/L‑OHP cells was significantly increased compared with that in HT‑29 cells (P<0.05). The relative expression of LAPTM4β‑35 protein in HT‑29/L‑OHP cells was significantly higher compared with that inHT‑29 cells (P<0.05). In conclusion, LAPTM4β may be involved in the multidrug resistance processes of CRC. Therefore, LAPTM4β may serve as a novel biomarker for drug resistance of CRC.

View Figures

View References

1	Takahashi K, Hosokawa M, Kasajima H, Hatanaka K, Kudo K, Shimoyama N and Miyashita K: Anticancer effects of fucoxanthin and fucoxanthinol on colorectal cancer cell lines and colorectal cancer tissues. Oncol Lett. 10:1463–1467. 2015.PubMed/NCBI
2	Geryk E, Horváth T and Konecný M: The expected worldwide burden of oesophagus, stomach and colorectal cancers. Vnitr Lek. 57:1006–1011. 2011.(In Czech). PubMed/NCBI
3	Bahl R, Arora S, Nath N, Mathur M, Shukla NK and Ralhan R: Novel polyumorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: Association with human esophageal cancer. Oncogene. 19:323–328. 2000. View Article : Google Scholar : PubMed/NCBI
4	Klintrup K, Mäkinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ and Mäkinen MJ: Inflammation and prognosis in colorectal cancer. Eur J Cancer. 41:2645–2654. 2005. View Article : Google Scholar : PubMed/NCBI
5	Ginés A, Bystrup S, de Porras Ruiz V, Guardia C, Musulén E, Martínez-Cardús A, Manzano JL, Layos L, Abad A and Martínez-Balibrea E: PKM2 subcellular localiczation is involved in oxaliplatin resistance acquisition in HT29 human colorectal cancer cell lines. PLoS One. 10:e01238302015. View Article : Google Scholar : PubMed/NCBI
6	Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
7	Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MV: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar : PubMed/NCBI
8	Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI
9	Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, Wei X and Ye DX: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 22:5060–5069. 2003. View Article : Google Scholar : PubMed/NCBI
10	Kasper G, Vogel A, Klaman I, Gröne J, Petersen I, Weber B, Castaños-Vélez E, Staub E and Mennerich D: The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett. 224:93–103. 2005. View Article : Google Scholar : PubMed/NCBI
11	Hogue DL, Kerby L and Ling V: A mammalian lysosomal membrane protein confers multidrug resistance upon expression in Saccharomyces cerevisiae. J Biol Chem. 274:12877–12882. 1999. View Article : Google Scholar : PubMed/NCBI
12	Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, Pang Y, Shan Y, Xiong FX, Shao GZ and Zhou RL: LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene. 29:5785–5795. 2010. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, et al: Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 16:214–218. 2010. View Article : Google Scholar : PubMed/NCBI
14	Milkereit R and Rotin D: A role for the ubiquitin ligase Nedd4 in membrane sorting of LAPTM4 proteins. PLoS One. 6:e274782011. View Article : Google Scholar : PubMed/NCBI
15	Xia LZ, Yin ZH, Ren YW, Shen L, Wu W, Li XL, Guan P and Zhou BS: The relationship between LAPTM4B polymorphisms and cancer risk in Chinese Han population: A meta-analysis. Springerplus. 4:1792015. View Article : Google Scholar : PubMed/NCBI
16	Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y and Huang Y: Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg. 204:677–683. 2012. View Article : Google Scholar : PubMed/NCBI
17	Jensen NF, Stenvang J, Beck MK, Hanáková B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, et al: Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Mol Oncol. 9:1169–1185. 2015. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, Danesi R and Mini E: Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updat. 14:280–296. 2011. View Article : Google Scholar : PubMed/NCBI
20	Pasquier E, Kavallaris M and André N: Metronomic chemotherapy: New rational for new directions. Nat Rev Clin Oncol. 7:455–465. 2010. View Article : Google Scholar : PubMed/NCBI
21	Joyce H, McCann A, Clynes M and Larkin A: Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol. 11:795–809. 2015. View Article : Google Scholar : PubMed/NCBI
22	Bhirde AA, Chikkaveeraiah BV, Srivatsan A, Niu G, Jin AJ, Kapoor A, Wang Z, Patel S, Patel V, Gorbach AM, et al: Targeted therapeutic nanotubes influence the viscoelasticity of cancer cells to overcome drug resistance. ACS Nano. 8:4177–4189. 2014. View Article : Google Scholar : PubMed/NCBI
23	Larsen AK, Escargueil AE and Skladanowski A: Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther. 85:217–229. 2000. View Article : Google Scholar : PubMed/NCBI
24	Gottesman MM: Mechanisms of cancer drug resistance. Ann Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
25	Cheng XJ, Xu W, Zhang QY and Zhou RL: Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers. Ann Oncol. 19:527–532. 2008. View Article : Google Scholar : PubMed/NCBI
26	Cheng X, Zheng Z, Bu Z, Wu X, Zhang L, Xing X, Wang X, Hu Y, Du H, Li L, et al: LAPTM4B-35, a cancer related gene, is associated with poor prognosis in TNM stages I–III gastric cancer patients. PLoS One. 10:e01215592015. View Article : Google Scholar : PubMed/NCBI
27	Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi C, Wang A, Sheng B, Li L and Xu Y: Overexpression of LAPTM4B-35: A novel marker of poor prognosis of prostate cancer. PLoS One. 9:e910692014. View Article : Google Scholar : PubMed/NCBI
28	Meng F, Luo C, Hu Y, Yin M, Lin M, Lou G and Zhou R: Overexpression of LAPTM4B-35 in cervical carcinoma: A clinicopathologic study. Int J Gynecol Pathol. 29:587–593. 2010. View Article : Google Scholar : PubMed/NCBI
29	Yang H, Xiong F, Qi R, Liu Z, Lin M, Rui J, Su J and Zhou R: LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol. 101:363–369. 2010. View Article : Google Scholar : PubMed/NCBI
30	Lee JT Jr, Steelman LS and McCubrey JA: Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein 1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 64:8397–8404. 2004. View Article : Google Scholar : PubMed/NCBI
31	Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmict M, Mills GB, Mendelsohn J and Fan Z: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003. View Article : Google Scholar : PubMed/NCBI
32	Abdul-Ghani R, Serra V, Györffy B, Jürchott K, Solf A, Dietel M and Schäfer R: The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene. 25:1743–1752. 2006. View Article : Google Scholar : PubMed/NCBI
33	Rad SM, Langroudi L, Kouhkan F, Yazdani L, Koupaee AN, Asgharpour S, Shojaei Z, Bamdad T and Arefian E: Transcription factor decoy: A pre-transcriptional approach for gene downregulation purpose in cancer. Tumour Biol. 36:4871–4881. 2015. View Article : Google Scholar : PubMed/NCBI
34	Barancík M, Bohácová V, Sedlák J, Sulová Z and Breier A: LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glysoprotein-mediated multidrug resistance. Eur J Pharm Sci. 29:426–434. 2006. View Article : Google Scholar : PubMed/NCBI
35	Li Y, Zhou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, et al: Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 16:214–218. 2010. View Article : Google Scholar : PubMed/NCBI
36	Tan X, Thapa Q, Sun Y and Anderson RA: A kinase-independent role for EGF receptor in autophagy initiation. Cell. 160:145–160. 2015. View Article : Google Scholar : PubMed/NCBI
37	Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, Iglehart JD, Wang ZC and Richardson AL: Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res. 71:7481–7489. 2011. View Article : Google Scholar : PubMed/NCBI